In the future, it is easy for a person to have two mothers. The British Bureau of Artificial Insemination and Embryology announced in its announcement 20 that an artificial insemination technology that would enable babies to have a parent, mother and trio of genetic material. After a public consultation, the majority of people support this new technology into clinical practice. In the practical phase, it will help the newborn to avoid certain genetic diseases in the future. According to the introduction of the Bureau of Artificial Insemination and Embryology, in the second half of last year, the Bureau collected opinions of the public on related issues through online questionnaires and holding public discussions. The results show that although some people are worried about the safety of new technologies and other issues, but most people support the technology. Zhejiang Ideal Bell Technolody Co., Ltd , https://www.idealpneumatics.com
As the current UK law prohibits such technologies involving the genetic modification of embryonic cells, the results of this investigation will be provided to the Parliament and the government as an important reference for discussing whether to amend the relevant laws. The mitochondrion is an organelle independent of the nucleus. It has its own genetic material and is only inherited by the mother. Mitochondrial abnormalities can cause many inherited diseases. One in 200 newborn babies in the UK suffers from mitochondrial defects associated with muscle weakness, intestinal dysfunction, and heart disease.
A parent and mother artificial insemination technology is expected to prevent related diseases from being transmitted to future generations. If a woman is found to have a disease associated with a mitochondrial defect, the researchers can remove the nucleus in one of her eggs and then implant the nucleus into a nucleus-derived egg donated by a mitochondria-sick woman. This egg eventually binds to his father's sperm and becomes a fertilized egg with healthy mitochondria.
At the same time, it is suggested that if the government releases new technologies, it should adopt relevant policies to strictly control them. For example, all clinics must be approved by the Artificial Insemination and Embryology Authority before clinical use of mitochondrial replacement technology. Mitochondrial providers should be treated as human tissue donors; unless the parties agree, newborns do not have access to mitochondrial provider personal information in the future.
In 2010, British researchers reported that they have developed mitochondrial replacement technology that can be used in humans and believe that it is expected to play an important role in medical care and improving the lives of related people. But the objections are that this is not a cure for the disease, but a problem with the creation of a new human embryo. This technology has changed the basic building blocks of the birth of life, and this change will continue to be inherited.